Time course of changes in carbohydrate and lipid metabolic parameters in patients with hypertensive disease during therapy with Rilmenidine versus Atenolol
https://doi.org/10.18705/1607-419X-2004-10-1-28-32
Abstract
The study has evaluated the impact of 26-week therapy with Rilmenidine, 1-2 mg daily, versus atenolol, 50-100 mg daily, on the parameters of 24-hour blood pressure monitoring, on the results of lipid phenotyping and oral glucose test in 37 patients with mild and moderate arterial hypertension (Stage II) during the randomized study. The antihypertensive effects of the drugs were comparable with a more significant decrease in heart rate in the atenolol group. At the same time, Rilmenidine showed good effects on the parameters of lipid metabolism and on the results of oral glucose tests as compared with atenolol whereas therapy with the latter resulted in deterioration of the blood lipid spectrum.
About the Authors
Yu. R. Kasherininov
НИИ кардиологии им. В.А.Алмазова Минздрава РФ
Russian Federation
Russian Federation
Ye. K. Shavarova
НИИ кардиологии им. В.А.Алмазова Минздрава РФ
Russian Federation
Russian Federation
A. A. Shavarov
НИИ кардиологии им. В.А.Алмазова Минздрава РФ
Russian Federation
Russian Federation
A. O. Konrádi
НИИ кардиологии им. В.А.Алмазова Минздрава РФ
Russian Federation
Russian Federation
Ye. V. Shlyakhto
НИИ кардиологии им. В.А.Алмазова Минздрава РФ
Russian Federation
Russian Federation
References
1. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antibypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (AĽĽHAT).JAMA 2002; 288:2981-97. 2.2003
2. European Society of Hypertension -European Society of cardiology Guidelinesfor the Management of Arterial HypertensionJ Hypertens 2003; 21: 1001-53.
3. The seventh report of Joint National Committeejn Prevention, Detection and treatment of high blood pressure (JNC VIl)Natiotuil Heart. Lung and Blood Institute, 2003-
4. Rabbia F, Martini G, Genova CG et al. Antihypertensive drugs and sympathetic nervous system. Clin Exp Hyperens 2001; 23:101-11.
5. Litchell H. Metabolic effects of antihypertensive drugs interacting with sympathetic nervous system. Eur HJ1992; 13 (Suppl. A): 53-7.
6. UKPDS and UKPDS 38. Br Med J 1998; 317: 707-20.
7. Bousquet P, Dontenwill M, Greney H, Feldman J. Imidazoline Receptors in Cardiovascular and Metabolic Diseases. J Cardiovasc Pharmacol 2000; 35 (suppl. 4): 21-5.
8. Рекомендации no профилактике, диагностике и лечению артериальной гипертензии. Артериальн. гипертенз. 2000; 7/1, приложение.
9. Dallocchio М, Gosse P,Fillastre JP. Rilmenidine, a New Antibypertensive Agent I The First Line Treatment of Essential Hypertension. Presse Med 1991; 20: 1265-71.
10. Julius S, Nesbitt S. Sympathetic Overaetivity in Hypertension: a Moving Target. Am J Hypertens 1996; 9· 113-20.
11. Алмазов B.A., Шляхто E.B., Соколова Л.А. Пограничная артериальная гипертензия. СПб: Гиппократ, 1992.
12. Krentz AJ, Evans AJ. Selective Imidazoline Receptors Agonists for Metabolic Syndrome. Lancet 1998; 351:152-4
13. Van Zwieten PA The Renaissance of Centrally Acting Antibypertensive Drugs. J Hypertens 1999; 17 (suppl. 3): 15-21.
14. De Luca N. Izzo R, Fontana D et al. Hemodynamic and Metabolic Effect of Rilmenidine in Hypertensive Patients with Metabolic Syndrome X. A Double-Blind Parallel Study versus Amlodipine. J Hyperteris 2000; 18: 10.
15. Небиеридзе ДВ. Рилменидин - один из первых представителей агонистов имидазолиновых рецепторов: новые возможности лечения артериальной гипертензии.Артериальн. гипертенз. 2002; 8 (4): 147-50.
16. Luccioni R. Pharmacoepidemiological Assessment of Hyperium (Rilmenidine) in 18235 Hypertensive Patients. Presse Med 1995; 24:1857-64
17. Reid JL. Update on Rilmenidine: Clinical Benefits. Am J Hypertens 2001; 14: 322-4
18. UK Prospective Diabetic Study (UKPDS) Group. Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS.
19. Luccioni R. Efficacy and Acceptability of Rilmenidine in 18235 Patients over One Year. Presse Med 1995; 124:1827-64-
20. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am J Med Sd 2001; 321 (4): 242-8.
Review
For citations:
Kasherininov Yu.R., Shavarova Ye.K., Shavarov A.A., Konrádi A.O., Shlyakhto Ye.V. Time course of changes in carbohydrate and lipid metabolic parameters in patients with hypertensive disease during therapy with Rilmenidine versus Atenolol. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2004;10(1):28-32. (In Russ.) https://doi.org/10.18705/1607-419X-2004-10-1-28-32
Views:
875
Email this article 